WFH publication explores challenges and opportunities of gene therapy

In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018 to initiate a global dialogue on the expected challenges and opportunities that a disruptive therapy, such as gene therapy, will bring to the hemophilia community. This cross‐sectoral meeting included representatives of 52 stakeholders from 21 countries, including healthcare professionals (HCP), scientific experts, regulators, payors, people with hemophilia (PWH) and advocates, pharmaceutical industry representatives and a medical ethicist. To read about this meeting and the key issues identified during the discussion, please see the published manuscript, “The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world” here.